Uses of Ridlor 75mg

Ridlor 75mg is a prescription medicine used to treat and prevent blood clots. To ensure safety for health and maximize the effectiveness of treatment, patients need to use drugs exactly as prescribed by the doctor/pharmacist.

Ridlor 75mg drug with the main ingredient is Clopidogrel is indicated to prevent the formation of blood clots in cerebrovascular accidents in patients with myocardial infarction (from a few days to about 35 days), stroke. transient (from 7 days to before 6 months) or established peripheral arterial disease.
The drug is in the form of film-coated tablets. Each film-coated tablet contains:
Clopidogrel Besylate 112.1mg which is equivalent to Clopidogrel 75mg. Excipients 1 capsule. Pharmacodynamics:
Clopidogrel is metabolised by CYP450 to the active metabolite that inhibits platelet aggregation. Pharmacokinetics:
Absorption: Following single and repeated oral doses of 75 mg daily, Clopidogrel is rapidly absorbed. Constant mean plasma concentrations of Clopiclogel (range 20-25 ng/ml after a single 75 mg dose) occurred approximately 45 minutes after dosing. The minimum absorption is 50%, based on urinary excretion of the metabolites of Clopidogrel. Effect of Feed : The effect of feed on the bioavailability of the parent compound or the active metabolite is not known at this time. Distribution: Clopidogrel and its major circulating inactive metabolite are reversibly bound to human serum proteins 94% and 98%, respectively. Binding to vitro is unsaturated up to concentrations of 100 mcg/ml. Metabolism: Clopidogrel is metabolised in the liver. Elimination: Following an oral dose of Ca in humans, approximately 50% of the total radioactivity dose is excreted in the urine and about 40% in the feces 5 days after oral administration. Following a single 75 mg oral dose, clopidogrel has a half-life of approximately 6 hours. The half-life of inactivated metabolic acid is 8 hours after single and repeated doses. Cohesive binding to platelets accounts for 2% of the radioactivity with a half-life of 11 days. In serum and urine, the glucuronide form of the carboxylic acid is also found.

When metabolized by the enzyme CYP450, the effect of Ridlor 75mg is to convert to a substance that inhibits platelet aggregation. This metabolite selectively inhibits Adenosine Diphosphate (ADP) binding to its P2Y12 platelet receptor and subsequent ADP.
Indications:
Primary prevention of disorders caused by thromboembolism such as myocardial infarction, stroke and peripheral arterial disease. Control and secondary prevention for atherosclerotic patients with recent stroke, recent myocardial infarction, or established peripheral artery disease. 3. Undesirable effects A number of undesirable effects have been reported with specific frequency as follows:
Common:
Hematoma, epistaxis; Gastrointestinal bleeding , diarrhea , abdominal pain and dyspepsia ; Bruised; Bleeding at the injection site. Uncommon:
Thrombocytopenia, white blood cell count and eosinophilia; Intracerebral hemorrhage, headache, fatigue, unusual sensations; Eye hemorrhage (conjunctiva, face, retina); Stomach - duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence; Itching, rash, bleeding under the skin (purpura), hematuria; Prolonged bleeding time, decreased neutrophils and platelets. Rare:
Neutropenia , m including severe neutropenia; Dizzy; Retroperitoneal bleeding. Very rare:
Thrombocytopenic purpura, aplastic anemia, pancytopenia, agranulocytosis, severe neutropenia, agranulocytosis, anemia; Taste disorder; Severe bleeding, open wound bleeding, vasculitis, hypotension; Respiratory tract hemorrhage (hemoptysis and pulmonary hemorrhage), bronchospasm, pulmonary interstitial inflammation; Gastrointestinal and retroperitoneal bleeding can cause death, pancreatitis, colitis; Acute liver failure, hepatitis, abnormal liver function test; Blister dermatitis including toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme; Edema, erythema, urticaria, eczema, lichen planus; Glomerulonephritis, increased serum creatinine, fever. If any side effects appear during use, please inform a qualified doctor or pharmacist for appropriate assistance.

Aspirin: A pharmacodynamic interaction between Clopidogrel and Aspirin may occur, leading to an increased risk of bleeding. Therefore, caution should be exercised when combining these two drugs. However, Clopidogrel and Aspirin can be combined for up to 1 year. Heparin: The pharmacodynamic interaction between Clopidogrel and Heparin may lead to an increased risk of bleeding. Therefore, the simultaneous use should be noted. Warfarin: May increase the risk of bleeding, so concomitant use of Clopidogrel and Warfarin should be considered. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): In a study in healthy volunteers receiving naproxen, the concomitant use of naproxen and clopidogrel was associated with an increase in potential gastrointestinal bleeding. Therefore, caution should be exercised when clopidogrel is co-administered with non-steroidal anti-inflammatory drugs. Drugs Metabolized by the Cytochrome P450 System: At high concentrations in vitro, clopidogrel inhibits Cytochrome P450 (2C9). It may therefore affect the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, furosemide, fluvastatin and many other non-steroidal anti-inflammatory agents, but there are no data on the severity of these interactions. Care should be taken when combining clopidogrel with these drugs. Other Combination Treatments: Concomitant use with drugs that inhibit CYP2C19 enzyme activity may decrease concentrations of the active metabolite Clopidogrel. Therefore, caution should be exercised when co-administering CYP2C19 inhibitors including Omeprazole and Esomeprazole, Fluvoxamine, Fluoxetine, Moclobemide, Voriconazole, Fluconazole, Ticlopidine, Ciprofloxacin, Cimetidine, Carbamazepine, Oxcarbazepine and Chloramphenicol.

How to use:
Ridlor 75mg is taken orally with or without food. Dosage:
Elderly and adults: A single dose of 75 mg clopidogrel per day is recommended. Genetic pharmacology: CYP2C19 poor metaboliser status associated with concomitant response to clopidogrel. The optimal dose for poor metabolisers has not been established. Pediatric patients: The safety and effectiveness of clopidogrel in children and adolescents have not been established. Renal impairment: There is little experience in the treatment of patients with renal failure. Hepatic impairment: There is little experience in the treatment of patients with moderate hepatic impairment with visceral bleeding. Note: The above dose is for your reference only. The specific dose will depend on the condition as well as the progression of the disease. When the right dose is available, you need to consult your doctor or medical professional.
Overdose due to use of Clopidogrel can lead to prolonged bleeding time and subsequent bleeding complications. Consider appropriate treatment if bleeding is observed.
There is no antidote to the pharmacological activity of Clopidogrel. If intervention is needed for prolongation of bleeding time, platelet transfusion may reverse the effects of Copidogrel.
In case of an emergency, call 911 immediately or go to the nearest local Health station.
When you forget to take an extra dose as soon as you remember it. However, if the interval between the next dose is too short, skip the missed dose and resume the dosing schedule. Do not take a double dose to make up for a missed dose.
6. Notes on drug use and storage Use on pregnant women and lactating mothers:
Pregnant women: There are no studies on the safety of the drug when used for pregnant women. Animal studies have not indicated harm to the fetus. However, you should consult your doctor before using the drug. Nursing Mothers: There is no evidence whether clopidogrel is excreted in human milk. Animal studies have shown that clopidogrel is excreted in human milk. The drug should not be used while breastfeeding. People who drive and operate machines:
Has no or negligible influence on the ability to drive and use machines. Other Special Notes:
When bleeding symptoms occur during treatment, close monitoring of blood cell counts or other appropriate tests is recommended. Should be used with caution in patients at increased risk of bleeding. The drug should be discontinued 7 days before surgery. Bleeding time may be longer than usual and patients should report any bleeding (location or duration) to the treating physician. Thrombocytopenic purpura has been reported very rarely following administration and is potentially fatal. Requires prompt treatment. It should not be used for the first 7 days after an acute transient stroke. Patients with inherited decreased CYP2C19 function may have reduced antiplatelet efficacy and higher rates of cardiovascular events after myocardial infarction than patients with normal function. There are limited data on the treatment of patients with renal and hepatic impairment at risk for visceral bleeding. Storage conditions:
Store in a dry place, the temperature is below 30 degrees C. Avoid direct sunlight. Keep out of reach of children. The article has helped you to add more information about what Ridlor medicine treats, how to use it as well as notes when using it. You need to carefully read the instructions for use, consult your doctor / pharmacist before use. Absolutely do not arbitrarily buy drugs to treat at home because there may be unwanted side effects.